Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol and Empagliflozin for Functional Tricuspid Regurgitation
NCT04345796Phase 3Completed
- Sponsor
- Asan Medical Center
- Start
- Feb 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of carvedilol, empagliflozin in functional tricuspid regurgitation (TR), sponsored by Asan Medical Center. Started Feb 2021; status: completed.
02
Drugs
carvedilolempagliflozin
03
Conditions
functional tricuspid regurgitation (TR)
Beyond the preview
Go deeper on NCT04345796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04345796.